Roth Capital Resumes Pieris Pharmaceuticals (PIRS) at Buy
Tweet
Share
E-mailGet Alerts PIRS Hot Sheet
Price: $13.60 --0%
Rating Summary:
8 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Rating Summary:
8 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Join SI Premium – FREE
Roth Capital resumed coverage on Pieris Pharmaceuticals (NASDAQ: PIRS) with a Buy rating and a price target of $6.00.
For an analyst ratings summary and ratings history on Pieris Pharmaceuticals click here. For more ratings news on Pieris Pharmaceuticals click here.
Shares of Pieris Pharmaceuticals closed at $1.70 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Starts Kanzhun Ltd. (BZ) at Neutral
- ThinkEquity Starts Deep Isolation Nuclear (DBHL) at Buy
- Wells Fargo Starts Huntington Bancshares (HBAN) at Overweight
Create E-mail Alert Related Categories
New CoverageRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
